CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.
CN Bio Innovations Ltd
CN Bio is a leading life sciences company. Our microfluidic technology improves drug discovery by generating human-relevant pre-clinical data in the lab, bridging gaps between traditional cell culture, animal studies, and human clinical trials to help develop safer, more effective, medicines, faster and reducing or replacing animal testing. Our Systems and Services facilitate deep insights into disease mechanisms, therapeutic efficacy and safety assessments.